400-920-2911 sales@csnpharm.cn
您的位置 : 首页 / Protein Tyrosine Kinase/RTK / HER2 & EGFR / Pyrotinib/吡咯替尼
CAS No.: 1269662-73-8
Synonyms: SHR-1258;吡咯替尼
Pyrotinib is an irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with HER2-Positive metastatic breast cancer.
生物活性
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|---|---|---|---|---|
NCT03756064 | Breast Cancer ... more >> Neoplasm, Breast Breast Diseases Collapse << | Not Applicable | Not yet recruiting | November 30, 2020 | - |
NCT02422199 | HER2 Positive Metastatic Breas... more >>t Cancer Collapse << | Phase 1 Phase 2 | Active, not recruiting | December 2018 | China, Beijing ... more >> Cancer Institute and Hospital, Chinese Academy of Medical Sciences Beijing, Beijing, China, 100021 China 307 Hospital Affiliated to Academy Military Medical Science Beijing, China Collapse << |
NCT02973737 | HER2 Positive Metastatic Breas... more >>t Cancer Collapse << | Phase 3 | Active, not recruiting | December 2019 | China ... more >> 307 Hospital Affiliated to Academy Military Medical Science Beijing, China Collapse << |
实验方案
技术信息
CAS号 | 1269662-73-8 | 储存条件 |
|
|
分子式 | C32H31ClN6O3 | 运输 | 蓝冰 | |
分子量 | 583.08 | 别名 | SHR-1258;吡咯替尼 |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|
NCT03756064 | Breast Cancer ... more >> Neoplasm, Breast Breast Diseases Collapse << | Not Applicable | Not yet recruiting | November 30, 2020 | - |
NCT02422199 | HER2 Positive Metastatic Breas... more >>t Cancer Collapse << | Phase 1 Phase 2 | Active, not recruiting | December 2018 | China, Beijing ... more >> Cancer Institute and Hospital, Chinese Academy of Medical Sciences Beijing, Beijing, China, 100021 China 307 Hospital Affiliated to Academy Military Medical Science Beijing, China Collapse << |
NCT02973737 | HER2 Positive Metastatic Breas... more >>t Cancer Collapse << | Phase 3 | Active, not recruiting | December 2019 | China ... more >> 307 Hospital Affiliated to Academy Military Medical Science Beijing, China Collapse << |
NCT03480256 | Gastric Cancer | Phase 1 | Not yet recruiting | August 2019 | China, Beijing ... more >> Beijing Cancer Hospital Not yet recruiting Beijing, Beijing, China, 100142 Contact: Shen Lin, Professor 010-88196561 Linshenpku@163.com Principal Investigator: Shen Lin, professor Department of GI Oncology, Peking University Cancer Hospital Not yet recruiting Beijing, Beijing, China, 100142 Contact: Jifang Gong, MD 861088196561 gongjifang@gmail.com Principal Investigator: Lin Shen, MD Collapse << |
NCT03588091 | HER2-positive Breast Cancer | Phase 3 | Recruiting | June 2022 | China ... more >> Fudan University Shanghai Cancer Center Recruiting Shanghai, China Contact: Jiong Wu, Dr. +86-13601637369 wujiong1122@vip.sina.com Collapse << |
NCT03080805 | HER2 Positive Metastatic Breas... more >>t Cancer Collapse << | Phase 3 | Recruiting | December 2019 | China, Beijing ... more >> Cancer Institute and Hospital,Chinese Academy of Medical Science Recruiting Beijing, Beijing, China Contact: Binghe Xu (+86) 010-87788114 xubinghe@medmail.com.cn Collapse << |
NCT03772353 | Breast Cancer | Phase 1 Phase 2 | Not yet recruiting | November 12, 2020 | China ... more >> Fudan University Shanghai Cancer Center Shanghai, China, 200032 Collapse << |
NCT02361112 | Metastatic Breast Cancer | Phase 1 | Completed | - | China, Beijing ... more >> Cancer Institute and Hospital, Chinese Academy of Medical Sciences Beijing, Beijing, China, 100029 Collapse << |
NCT03412383 | Breast Cancer ... more >> HER2 Gene Mutation Collapse << | Phase 2 | Recruiting | June 25, 2019 | China, Beijing ... more >> Fei Ma Recruiting Beijing, Beijing, China, 100021 Contact: Fei Ma, MD +86-10-87787652 mafei@126.com Collapse << |
NCT03691051 | HER2 Positive Metastatic Breas... more >>t Cancer Collapse << | Phase 2 | Not yet recruiting | November 20, 2020 | - |
NCT02834936 | Non Small Cell Lung | Phase 2 | Recruiting | June 2018 | China, Shanghai ... more >> Shanghai Pulmonary Hospital Recruiting Shanghai, Shanghai, China, 200433 Contact: Caicun Zhou, M. D. caicunzhoudr@126.com China HR-BLTN-II-NSCLC Investigational Site Recruiting Beijing, China Contact: Jiangang Yu 18036618602 yujiangang@shhrp.com HR-BLTN-II-NSCLC Investigational Site Recruiting Changsha, China Contact: Jiangang Yu 18036618602 yujiangang@shhrp.com HR-BLTN-II-NSCLC Investigational Site Not yet recruiting Guangzhou, China HR-BLTN-II-NSCLC Investigational Site Recruiting Hangzhou, China Contact: Jiangang Yu 18036618602 yujiangang@shhrp.com HR-BLTN-II-NSCLC Investigational Site Recruiting Harbin, China Contact: Jiangang Yu 18036618602 yujiangang@shhrp.com HR-BLTN-II-NSCLC Investigational Site Recruiting Nanjing, China Contact: Jiangang Yu 18036618602 yujiangang@shhrp.com HR-BLTN-II-NSCLC Investigational Site Not yet recruiting Shanghai, China Contact: Jiangang Yu 18036618602 yujiangang@shhrp.com HR-BLTN-II-NSCLC Investigational Site Recruiting Suzhou, China Contact: Jiangang Yu 18036618602 yujiangang@shhrp.com HR-BLTN-II-NSCLC Investigational Site Not yet recruiting Wuhan, China HR-BLTN-II-NSCLC Investigational Site Recruiting Zhengzhou, China Contact: Jiangang Yu 18036618602 yujiangang@shhrp.com Collapse << |
NCT03735966 | HER2 Positive Breast Cancer | Phase 2 | Not yet recruiting | November 20, 2024 | - |
NCT02500199 | Breast Cancer ... more >> Gastric Cancer Solid Tumors NSCLC Collapse << | Phase 1 | Recruiting | March 2020 | United States, Florida ... more >> Florida Cancer Specialists Recruiting Sarasota, Florida, United States, 34232 Contact: Manish Patel, MD 941-377-9993 mpatel@flcancer.com Principal Investigator: Manish Patel, MD United States, Massachusetts Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Alice Shaw, MD,Ph.D 617-724-4000 ashaw1@partners.org Principal Investigator: Alice Shaw, MD Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Brian Beardslee 617-632-5638 brian_beardslee@dfci.harvard.edu Principal Investigator: Geoffrey Shapiro, MD United States, Michigan Henry Ford Health System Recruiting Detroit, Michigan, United States, 48202 Contact: Ding Wang 313-916-3721 dwang1@hfhs.org Principal Investigator: Ding Wang, MD United States, Missouri Washington University Recruiting Saint Louis, Missouri, United States, 63110 Contact: Cindy Fogal 314-362-1518 cfogal@wustl.edu Principal Investigator: Saiama Waqar, MD United States, New York Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Caileigh Mcgoldrick 646-888-4226 Principal Investigator: Bob Li, MD United States, Tennessee Tennessee Oncology Recruiting Nashville, Tennessee, United States, 37203 Contact: Melisa Johnson, MD mjohnson@tnonc.com Principal Investigator: Melissa Johnson, MD United States, Texas South Texas Accelerated Research Therapeutics Completed San Antonio, Texas, United States, 78229 Collapse << |
NCT02378389 | HER2 Positive Gastric Cancer | Phase 1 | Unknown | August 2017 | China, Beijing ... more >> Beijing Cancer Hospital, Peking University Recruiting Beijing, Beijing, China, 100037 Contact: Lin Shen, M.D 010-88196391 Principal Investigator: Lin Shen, M.D Cancer Hospital, Chinese Academy of Medical Sciences Not yet recruiting Beijing, Beijing, China Contact: Jing Huang Chinese PLA General Hospital Not yet recruiting Beijing, Beijing, China Contact: Guanghai Dai China, Guangdong Cancer center, Sun Yet-sen University Recruiting Guangzhou, Guangdong, China Contact: Ruihua Xu 020-87343135 Principal Investigator: Ruihua Xu, M.D Collapse << |
NCT01937689 | Breast Cancer | Phase 1 | Completed | - | China, Beijing ... more >> Cancer Institute and Hospital, Chinese Academy of Medical Sciences Beijing, Beijing, China, 100021 Collapse << |
NCT02535507 | Non-small Cell Lung Cancer | Phase 2 | Unknown | December 2017 | China ... more >> Department of Oncology, Shanghai pulmonary hospital Recruiting Shanghai, China, 200433 Contact: Caicun zhou, MD, PhD 86-65115006-3050 caicunzhoudr@126.com Contact: shengxiang Ren, MD,PhD harry_ren@126.com Sub-Investigator: Shengxiang Ren, MD,PhD Sub-Investigator: Fengying Wu, MD, Sub-Investigator: Xiaoxia Chen, MD,PhD Sub-Investigator: Chunxia Su, MD,PhD Principal Investigator: Caicun Zhou, MD,PhD Collapse << |
联系我们
官方电话:400-920-2911
二维码
微信公众号 CSN官网